NUTX Nutex Health Inc

$NUTX into Q3: Earnings. Q2 diluted EPS $9.38 vs $4.95 consensus, an 89% beat. Even excluding the one-time $52M accrual release, clean EPS was ~$5.80, above the Street. H1 operating income $203M, up 78% YoY. Operating cash flow $110M in six months. Trailing EPS: $25.24. Valuation. Closed $205.01 on Oct 8. That's 8.1x trailing and 7.9x forward earnings. Peers: Tenet 12.4x forward, HCA 14.5x, Encompass 19.0x. B. Riley raised its target to $325 on Sept 4. Five analysts, all Buy, average target $283, median $300. Balance sheet. $205M cash against $40M of conventional debt (the hospital buildings sit in finance leases, as with any operator). Buyback retired 4.4% of shares in six months, 7.09M to 6.84M. The earn-out dilution overhang is finished: the Aug 4 count including every remaining issuable share is 6,847,973, about 4,000 above outstanding. Positioning. Short interest 1,234,054 shares at the Sept 15 settlement, highest in the stock's history: 18% of shares outstanding, 29.8% of a 4.15M float, 7.5 days to cover. Shorts added 71,553 shares in the exact two weeks the stock ran to all-time highs. No listed options exist on NUTX. The only way out of a short is the tape. Track record. 8 of the last 11 reports were followed by an up session, median +13%. Every clean quarter with an EPS beat, 8 of 8, closed higher the next day. All three down reactions involved a filing issue, none a fundamental miss. Growth. 28 facilities in 12 states, 7 more in development through 2027, 3-5 openings per year. $5-6M capex each, cash-flow positive within year one, with a board-approved sale-leaseback model to fund future builds. The company shrinks the float every quarter. The shorts grow their position every settlement. Long NUTX. See you after the report in Nov.

$NUTX an other great quarter. Cash machine. Year over year comparisons don’t make sense as they changed how they do accounting at the beginning of this year.

$NUTX Holding $200 really well and has bounced off the floor several times. Lots of buyer strength, good stuff and can hopefully expect it to hold until earnings this time next month. 🙏

$NUTX Q3: clean beat, lower costs, record volumes. Volume: hospital visits +18.1% YoY, same-hospital +12.4%. Best same-store growth in the company's history. More patients, same buildings. No accounting involved. Costs: arbitration expense $27.8M vs $41.9M a year ago, down 34% on higher volume. Management guided 25-30%. They beat their own number. The HaloMD amendment and the CMS fee cut are now in the P&L, and this was the first full quarter with both. IDR: win rate >80%, collection rate >80%, holding exactly where they've been. The engine the short report said would seize up is running at the same speed. Earnings: $5.71 diluted vs $5.53 consensus. Clean. No one-time items, no accrual releases, no reconciliations. Nine-month EPS $21.50 vs $8.87 a year ago. Cash: $249.9M, up $44M in thirteen weeks. Conventional debt $42M. That's roughly $30 a share of net cash on a stock at ~8x earnings. Float: 6,857,504 shares outstanding, down from 7.09M at year-end, and still shrinking. Short interest sits at 30% of that float. Two more hospitals open in Q4. So, the bear talking point: revenue -18.7% YoY and EBITDA margin down from 37% to 29%. But read the comp! Q3 2025 carried collection true-ups on 2024 claims and sat ahead of a Q4 2025 reconciliation that pulled ineligible charts out of the base. Last year's number was inflated by catch-up; this year's is the clean run-rate. Revenue per visit has reset to a sustainable level while visits grow double digits, which is exactly the base you want to compound from. And the margin is 29% on a normalized quarter, not 37% on a flattered one. Still top-tier for hospital operators. Still generating $78M of operating cash flow in a single quarter. Nine months in: $645M revenue, $153M net income, $188M operating cash flow, $280M operating income. Peers trade at 12-19x forward. Street average target $323. Highest $336. Net: cleaner base, lower costs, higher volumes, more cash, fewer shares. Long NUTX.

$NUTX They will be opening 2 new hospitals in Q4 2026. That's the tailwind for the company. It'll go higher once we get closer to the opening. More clarity is required for the increase in patients traffic, but the decline in revenue.

$NUTX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $5.71 down -26.42% YoY • Reported revenue of $217.61M down -18.74% YoY

$NUTX the short sellers didnt get the news they were looking for. If the short interest decreases much healthier for the stock

$NUTX why do you think the short sellers are so negative. 1.2 million shorts worth 200 million they must think it will collapse. Why? Revenue number was weaker than expected last quarter but what matters the eps was total blow out